Table 4.

Effect of NXY-059 on infarct volume by brain region subdivided by animal species and sex, and model of ischaemia

Group	Experiments	Animals	Coefficient	95% CI	P-value
Species
Total	18	442	−0.03	−0.04 to −0.02	<0.0001
Mice	1	9	−8.67	−19.69 to 2.36	0.12
Rats	15	401	−0.03	−0.04 to −0.02	<0.0001
Marmosets	2	32	−0.06	−0.10 to −0.01	0.01
Males	2	17	−0.02	−0.06 to 0.01	0.13
Females	2	15	−0.05	−0.09 to −0.005	0.03
Cortical†	4	111	−0.08	−0.11 to −0.06	<0.0001
Rats	2	79	−0.13	−0.16 to −0.10	<0.0001
Marmosets	2	32	−0.04	−0.09 to 0.003	0.07
Males	2	17	−0.03	−0.10 to 0.03	0.32
Females	2	15	−0.04	−0.08 to 0.01	0.13
Subcortical†	4	111	−0.10	−0.13 to −0.08	<0.0001
Rats	2	79	−0.13	−0.16 to −0.10	<0.0001
Marmosets	2	32	−0.07	−0.11 to −0.02	0.002
Males	2	17	−0.06	−0.13 to 0.01	0.11
Females	2	15	−0.07	−0.11 to −0.03	0.001
Model
Total
Transient	6	160	−0.05	−0.08 to −0.03	<0.0001
Permanent	11	258	−0.10	−0.13 to −0.08	<0.0001
Thrombotic	1	24	−0.06	−0.15 to 0.03	0.18

No data were available for cortical/subcortical volumes in mice. Analyses based on individual animal data only. Data are coefficients per 100 mg·kg⁻¹ of total administered NXY-059 dose with standardization for model and adjustment for time to treatment; 95% confidence intervals (95% CI) and significance. Results in bold are statistically significant.

^†Permanent models only.

NXY-059, disodium 2,4-disulphophenyl-N-tert-butylnitrone.